BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 16625682)

  • 1. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
    J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors.
    Chan WY; Wo NC; Stoev S; Cheng LL; Manning M
    Br J Pharmacol; 1998 Oct; 125(4):803-11. PubMed ID: 9831918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and design of novel vasopressin hypotensive peptide agonists.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Recept Signal Transduct Res; 1999; 19(1-4):631-44. PubMed ID: 10071789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
    J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
    Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
    J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
    J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template.
    Wilczynski A; Wilson KR; Scott JW; Edison AS; Haskell-Luevano C
    J Med Chem; 2005 Apr; 48(8):3060-75. PubMed ID: 15828845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
    Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
    Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.